Spero Therapeutics (SPRO) Amortizatization of Intangibles (2018 - 2022)
Spero Therapeutics' (SPRO) quarterly Amortizatization of Intangibles came in at $10000.0 in Q2 2022, up 116.67% YoY from $4615.4 in Q2 2021, and up 143.48% on a QoQ basis from -$23000.0 in Q1 2022.
Spero Therapeutics (SPRO) Amortizatization of Intangibles (2018 - 2022) Analysis & Trends
Spero Therapeutics (SPRO) has 5 years of Amortizatization of Intangibles data on file, last reported at $10000.0 in Q2 2022.
- Quarterly Amortizatization of Intangibles rose 116.67% year-over-year to $10000.0 in Q2 2022, while the trailing twelve-month figure through Mar 2023 was $10000.0 (up 104.76% YoY) and the FY2022 annual result came in at -$13000.0, up 94.82% from the prior year.
- Amortizatization of Intangibles climbed to $10000.0 in Q2 2022, from -$23000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $355000.0 in Q1 2019 to a low of -$73000.0 in Q3 2021.
- A 5-year average of $66055.6 and a median of $27500.0 in 2018 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2019 — Amortizatization of Intangibles surged 688.89% — and 2021, when it tumbled 3550.0%.
- Tracing SPRO's Amortizatization of Intangibles over 5 years: stood at $325000.0 in 2018, then sank by 73.23% to $87000.0 in 2019, then slumped by 128.74% to -$25000.0 in 2020, then slumped by 116.0% to -$54000.0 in 2021, then soared by 118.52% to $10000.0 in 2022.
- The last three Amortizatization of Intangibles figures came in at $10000.0 (Q2 2022), -$23000.0 (Q1 2022), and -$54000.0 (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Spero Therapeutics | 70.72 Mn | 19.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 10,000.00 |
| Jun 30, 2022 | 10,000.00 |
| Mar 31, 2022 | -23,000.00 |
| Mar 31, 2022 | -23,000.00 |
| Dec 31, 2021 | -54,000.00 |
| Dec 31, 2021 | -54,000.00 |
| Sep 30, 2021 | -73,000.00 |
| Sep 30, 2021 | -73,000.00 |
| Jun 30, 2021 | -60,000.00 |
| Jun 30, 2021 | -60,000.00 |
| Mar 31, 2021 | -64,000.00 |
| Mar 31, 2021 | -64,000.00 |
| Dec 31, 2020 | -25,000.00 |
| Dec 31, 2020 | -25,000.00 |
| Sep 30, 2020 | -2,000.00 |
| Sep 30, 2020 | -2,000.00 |
| Jun 30, 2020 | 6,000.00 |
| Jun 30, 2020 | 6,000.00 |
| Mar 31, 2020 | 53,000.00 |
| Mar 31, 2020 | 53,000.00 |